Clinical Trial Update: Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial assesses the efficacy and safety of Lumiracoxib 400 mg once daily for acute gout flares; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gouty Arthritis

Drugs mentioned

• Lumiracoxib (Lumiracoxib)

Snippet

Sponsor: Novartis | Conditions: Acute Gouty Arthritis | Phase 4 | Status: COMPLETED